Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study.
Fariborz
F
Mobarrez
Nils
N
Egberg
Jovan
J
Antovic
Anders
A
Bröijersen
Gun
G
Jörneskog
Håkan
H
Wallén
D000368:Aged; D015703:Antigens, CD / Q000097:blood; D000069059:Atorvastatin; D015415:Biomarkers / Q000097:blood; D015820:Cadherins / Q000097:blood; D055252:Cell-Derived Microparticles / Q000187:drug effects* / Q000276:immunology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood / Q000188:drug therapy*; D010919:Placebos; D011758:Pyrroles / Q000627:therapeutic use*; D013548:Sweden; D013925:Thromboplastin / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D000099152:Cadherin 5
D015703:Antigens, CD; D000069059:Atorvastatin; D015415:Biomarkers; D015820:Cadherins; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010919:Placebos; D011758:Pyrroles; D013925:Thromboplastin; D000099152:Cadherin 5